A Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of LYC-30937-EC in Subjects With Moderate Chronic Plaque-Type Psoriasis
Latest Information Update: 11 Apr 2019
Price :
$35 *
At a glance
- Drugs Parimifasor (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms UPRISE
- Sponsors Lycera
- 25 Jul 2017 Status changed from recruiting to completed.
- 27 Mar 2017 Planned End Date changed from 1 Jul 2017 to 1 Jun 2017.
- 23 Feb 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Jun 2017.